Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01761266




Registration number
NCT01761266
Ethics application status
Date submitted
2/01/2013
Date registered
4/01/2013
Date last updated
5/04/2022

Titles & IDs
Public title
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Scientific title
A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Secondary ID [1] 0 0
2012-002992-33
Secondary ID [2] 0 0
E7080-G000-304
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatocellular Carcinoma (HCC) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Liver

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Lenvatinib
Treatment: Drugs - Sorafenib

Active comparator: Lenvatinib - Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Active comparator: Sorafenib - Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.


Treatment: Drugs: Lenvatinib
12 mg (or 8 mg) once daily (QD) oral dosing.

Treatment: Drugs: Sorafenib
400 mg twice daily (BID) oral dosing.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
From date of randomization until date of death from any cause (approximately up to 3.8 years)
Secondary outcome [1] 0 0
Progression Free Survival (PFS)
Timepoint [1] 0 0
From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
Secondary outcome [2] 0 0
Time to Progression (TTP)
Timepoint [2] 0 0
The time from the date of randomization to the date of first documentation of disease progression (approximately up to 3.8 years)
Secondary outcome [3] 0 0
Objective Response Rate (ORR)
Timepoint [3] 0 0
From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
Secondary outcome [4] 0 0
Time to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Timepoint [4] 0 0
Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
Secondary outcome [5] 0 0
Time to Clinically Meaningful Worsening of HRQoL Assessed Using - EORTC QLQ- Hepatocellular Carcinoma Domain (HCC 18)
Timepoint [5] 0 0
Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
Secondary outcome [6] 0 0
Time to Clinically Meaningful Worsening of HRQoL Assessed Using EuroQol Five Dimension Health Questionnaire (EQ-5D-3L)
Timepoint [6] 0 0
Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
Secondary outcome [7] 0 0
Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib
Timepoint [7] 0 0
Cycle 1 Day 1, Cycle 2 Day 1: pre-dose, 0.5-4 and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 2-12 hours post-dose (cycle length= 28 days)

Eligibility
Key inclusion criteria
1. Participants must have confirmed diagnosis of unresectable HCC with any of the following criteria:

* Histologically or cytologically confirmed diagnosis of HCC.
* Clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology or with chronic hepatitis B or C infection criteria
2. At least one measurable target lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) meeting the following criteria:

• Hepatic lesion
1. The lesion can be accurately measured in at least one dimension as >=1.0 centimeter (cm) (viable tumor for typical; and longest diameter for atypical), and
2. The lesion is suitable for repeat measurement.

• Nonhepatic lesion
3. Lymph node (LN) lesion that measures at least one dimension as >=1.5 cm in the short axis, except for porta hepatis LN that measures >=2.0 cm in the short axis.
4. Non-nodal lesion that measures >=1.0 cm in the longest diameter Lesions previously treated with radiotherapy or locoregional therapy must show radiographic evidence of disease progression to be deemed a target lesion.
3. Participants categorized to stage B (not applicable for transarterial chemoembolization [TACE]) or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system.
4. Adequate bone marrow function, defined as:

* Absolute neutrophil count (ANC) >=1.5 X 10^9 per liter (/L)
* Hemoglobin (Hb) >=8.5 gram per deciliter (g/dL)
* Platelet count >=75 X 10^9/L.
5. Adequate liver function, defined as:

* Albumin >=2.8 g/dL
* Bilirubin less than or equal to (<=) 3.0 mg/dL
* Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) <=5 X the upper limit of normal (ULN).
6. Adequate blood coagulation function, defined as international normalized ratio (INR) <=2.3.
7. Adequate renal function defined as creatinine clearance greater than (>) 40 milliliter per minute (mL/min) calculated per the Cockcroft and Gault formula.
8. Adequate pancreatic function, defined as amylase and lipase <=1.5 X ULN.
9. Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents, defined as BP <=150/90 millimeters of mercury (mmHg) at Screening and no change in antihypertensive therapy within 1 week prior to the Cycle1/Day1.
10. Child-Pugh score A.
11. Eastern Cooperative Oncology Group (ECOG)- performance status (PS) 0 or 1.
12. Males or females aged at least 18 years (or any age >18 years as determined by country legislation) at the time of informed consent.
13. Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of 25 International Units Per Liter (IU/L) or equivalent units of BhCG).

A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
14. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with surgery at least 1 month before dosing).
15. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (e.g., total abstinence, an intrauterine device, a double barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the participant must agree to use a double barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
16. Male participants must have had a successful vasectomy (confirmed azoospermia) or they and their female partners must meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed during the study period and for 30 days after study drug discontinuation.
17. Provide written informed consent.
18. Willing and able to comply with all aspects of the protocol.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

1. Imaging findings for HCC corresponding to any of the following:

* HCC with >=50 percent liver occupation
* Clear invasion into the bile duct
* Portal vein invasion at the main portal branch (Vp4).
2. Participants who have received any systemic chemotherapy, including anti-vascular endothelial growth factor (VEGF) therapy, or any systemic investigational anticancer agents, including lenvatinib, for advanced/unresectable HCC. Note: Participants who have received local hepatic injection chemotherapy are eligible.
3. Participants who have received any anticancer therapy (including surgery, percutaneous ethanol injection, radio frequency ablation, transarterial [chemo] embolization, hepatic intra-arterial chemotherapy, biological, immunotherapy, hormonal, or radiotherapy) or any blood enhancing treatment (including blood transfusion, blood products, or agents that stimulate blood cell production, eg, granulocyte colony-stimulating factor [G-CSF]) within 28 days prior to randomization.
4. Participants who have not recovered from toxicities as a result of prior anticancer therapy, except alopecia and infertility. Recovery is defined as < Grade 2 severity per Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).
5. Significant cardiovascular impairment: history of congestive heart failure > New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening.
6. Prolongation of corrected QT interval (QTc) interval to >480 millisecond (ms)
7. Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib in the opinion of the investigator.
8. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR monitoring, eg, warfarin or similar agents. Treatment with low molecular weight heparin and factor X inhibitors which do not require INR monitoring is permitted. Antiplatelet agents are prohibited throughout the study.
9. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 28 days prior to randomization.
10. Gastric or esophageal varices that require interventional treatment within 28 days prior to randomization. Prophylaxis with pharmacologic therapy (eg, nonselective beta-blocker) is permitted.
11. Active malignancy (except for HCC or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 36 months.
12. Participants whose only target lesion(s) is in bone will be excluded.
13. Meningeal carcinomatosis.
14. Any history of or current brain or subdural metastases.
15. Participants having >1+ proteinuria on urine dipstick testing will undergo a 24-hour urine collection for quantitative assessment of proteinuria. Participants with a urine protein >=1g/24 hours will be ineligible.
16. Surgical arterial-portal venous shunt or arterial-venous shunt.
17. Any medical or other condition that in the opinion of the investigator would preclude the participant's participation in a clinical study.
18. Known intolerance to lenvatinib or sorafenib (or any of the excipients).
19. Human immunodeficiency virus (HIV) positive or active infection requiring treatment (except for hepatitis virus).
20. Any history of drug or alcohol dependency or abuse within the prior 6 months.
21. Any participant who cannot be evaluated by either triphasic liver computed tomography (CT) or triphasic liver Magnetic resonance imaging (MRI) because of allergy or other contraindication to both CT and MRI contrast agents.
22. Major surgery within 3 weeks prior to randomization or scheduled for surgery during the study.
23. Participants has had a liver transplant.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/03/2021
Sample size
Target
Accrual to date
Final
954
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Facility # 1 - Camperdown
Recruitment hospital [2] 0 0
Facility # 1 - Wentworthville
Recruitment hospital [3] 0 0
Facility # 1 - Woolloongabba
Recruitment hospital [4] 0 0
Facility # 1 - Fitzroy
Recruitment hospital [5] 0 0
Facility # 1 - Melbourne
Recruitment hospital [6] 0 0
Facility # 2 - Melbourne
Recruitment hospital [7] 0 0
Facility # 1 - Nedlands
Recruitment postcode(s) [1] 0 0
- Camperdown
Recruitment postcode(s) [2] 0 0
- Wentworthville
Recruitment postcode(s) [3] 0 0
- Woolloongabba
Recruitment postcode(s) [4] 0 0
- Fitzroy
Recruitment postcode(s) [5] 0 0
- Melbourne
Recruitment postcode(s) [6] 0 0
- Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
District of Columbia
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
New Jersey
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Oregon
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
Belgium
State/province [14] 0 0
Bruxelles
Country [15] 0 0
Belgium
State/province [15] 0 0
Edegem
Country [16] 0 0
Belgium
State/province [16] 0 0
Liege
Country [17] 0 0
Canada
State/province [17] 0 0
Ontario
Country [18] 0 0
China
State/province [18] 0 0
Anhui
Country [19] 0 0
China
State/province [19] 0 0
Beijing
Country [20] 0 0
China
State/province [20] 0 0
Chongqing
Country [21] 0 0
China
State/province [21] 0 0
Fujian
Country [22] 0 0
China
State/province [22] 0 0
Guangdong
Country [23] 0 0
China
State/province [23] 0 0
Heilongjiang
Country [24] 0 0
China
State/province [24] 0 0
Hunan
Country [25] 0 0
China
State/province [25] 0 0
Jiangsu
Country [26] 0 0
China
State/province [26] 0 0
Jilin
Country [27] 0 0
China
State/province [27] 0 0
Liaoning
Country [28] 0 0
China
State/province [28] 0 0
Shandong
Country [29] 0 0
China
State/province [29] 0 0
Shanghai
Country [30] 0 0
China
State/province [30] 0 0
Shanxi
Country [31] 0 0
China
State/province [31] 0 0
Zhejiang
Country [32] 0 0
France
State/province [32] 0 0
Alpes Maritimes
Country [33] 0 0
France
State/province [33] 0 0
Gironde
Country [34] 0 0
France
State/province [34] 0 0
Haute Garonne
Country [35] 0 0
France
State/province [35] 0 0
Herault
Country [36] 0 0
France
State/province [36] 0 0
Ille Et Vilaine
Country [37] 0 0
France
State/province [37] 0 0
Meurthe Et Moselle
Country [38] 0 0
France
State/province [38] 0 0
Somme
Country [39] 0 0
France
State/province [39] 0 0
Val De Marne
Country [40] 0 0
France
State/province [40] 0 0
Bordeaux
Country [41] 0 0
France
State/province [41] 0 0
Lille cedex
Country [42] 0 0
France
State/province [42] 0 0
Lyon
Country [43] 0 0
France
State/province [43] 0 0
Nord
Country [44] 0 0
France
State/province [44] 0 0
Paris cedex 12
Country [45] 0 0
France
State/province [45] 0 0
Paris
Country [46] 0 0
France
State/province [46] 0 0
Rhone
Country [47] 0 0
Germany
State/province [47] 0 0
Baden Wuerttemberg
Country [48] 0 0
Germany
State/province [48] 0 0
Hessen
Country [49] 0 0
Germany
State/province [49] 0 0
Niedersachsen
Country [50] 0 0
Germany
State/province [50] 0 0
Nordrhein Westfalen
Country [51] 0 0
Germany
State/province [51] 0 0
Rheinland Pfalz
Country [52] 0 0
Hong Kong
State/province [52] 0 0
Hong Kong
Country [53] 0 0
Hong Kong
State/province [53] 0 0
Kowloon
Country [54] 0 0
Israel
State/province [54] 0 0
Petach Tikva
Country [55] 0 0
Israel
State/province [55] 0 0
Petah Tiqwa
Country [56] 0 0
Italy
State/province [56] 0 0
Ancona
Country [57] 0 0
Italy
State/province [57] 0 0
Bari
Country [58] 0 0
Italy
State/province [58] 0 0
Benevento
Country [59] 0 0
Italy
State/province [59] 0 0
Bologna
Country [60] 0 0
Italy
State/province [60] 0 0
Napoli
Country [61] 0 0
Italy
State/province [61] 0 0
Palermo
Country [62] 0 0
Italy
State/province [62] 0 0
Roma
Country [63] 0 0
Japan
State/province [63] 0 0
Aichi
Country [64] 0 0
Japan
State/province [64] 0 0
Chiba
Country [65] 0 0
Japan
State/province [65] 0 0
Ehime
Country [66] 0 0
Japan
State/province [66] 0 0
Fukuoka
Country [67] 0 0
Japan
State/province [67] 0 0
Hokkaido
Country [68] 0 0
Japan
State/province [68] 0 0
Hyogo
Country [69] 0 0
Japan
State/province [69] 0 0
Ishikawa
Country [70] 0 0
Japan
State/province [70] 0 0
Kanagawa
Country [71] 0 0
Japan
State/province [71] 0 0
Mie
Country [72] 0 0
Japan
State/province [72] 0 0
Nagasaki
Country [73] 0 0
Japan
State/province [73] 0 0
Osaka
Country [74] 0 0
Japan
State/province [74] 0 0
Tokyo
Country [75] 0 0
Japan
State/province [75] 0 0
Yamaguchi
Country [76] 0 0
Japan
State/province [76] 0 0
Hiroshima
Country [77] 0 0
Japan
State/province [77] 0 0
Okayama
Country [78] 0 0
Japan
State/province [78] 0 0
Saga
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Gyeonggi-do
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Gyeongsangbuk-do
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Jeollanam-do
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Busan
Country [83] 0 0
Korea, Republic of
State/province [83] 0 0
Incheon
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Seoul
Country [85] 0 0
Malaysia
State/province [85] 0 0
Pahang
Country [86] 0 0
Malaysia
State/province [86] 0 0
Pulau Pinang
Country [87] 0 0
Malaysia
State/province [87] 0 0
Sarawak
Country [88] 0 0
Malaysia
State/province [88] 0 0
Selangor
Country [89] 0 0
Malaysia
State/province [89] 0 0
Kuala Lumpur
Country [90] 0 0
Philippines
State/province [90] 0 0
Cebu City
Country [91] 0 0
Philippines
State/province [91] 0 0
Davao City
Country [92] 0 0
Philippines
State/province [92] 0 0
Quezon City
Country [93] 0 0
Poland
State/province [93] 0 0
Gdansk
Country [94] 0 0
Poland
State/province [94] 0 0
Warszawa
Country [95] 0 0
Poland
State/province [95] 0 0
Wroclaw
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Arkhangelsk
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Moscow
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Saint Petersburg
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Ufa
Country [100] 0 0
Singapore
State/province [100] 0 0
Singapore
Country [101] 0 0
Spain
State/province [101] 0 0
Barcelona
Country [102] 0 0
Spain
State/province [102] 0 0
Cantabria
Country [103] 0 0
Spain
State/province [103] 0 0
Badajoz
Country [104] 0 0
Spain
State/province [104] 0 0
Girona
Country [105] 0 0
Spain
State/province [105] 0 0
Madrid
Country [106] 0 0
Taiwan
State/province [106] 0 0
Kaohsiung
Country [107] 0 0
Taiwan
State/province [107] 0 0
Taichung
Country [108] 0 0
Taiwan
State/province [108] 0 0
Tainan
Country [109] 0 0
Taiwan
State/province [109] 0 0
Taipei
Country [110] 0 0
Taiwan
State/province [110] 0 0
Taoyuan City
Country [111] 0 0
Thailand
State/province [111] 0 0
Bangkok
Country [112] 0 0
Thailand
State/province [112] 0 0
Chiang Mai
Country [113] 0 0
Thailand
State/province [113] 0 0
Chiang Rai
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Greater London
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Greater Manchester
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Merseyside
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Strathclyde
Country [118] 0 0
United Kingdom
State/province [118] 0 0
West Midlands

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eisai Limited
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable Hepatocellular Carcinoma (HCC).
Trial website
https://clinicaltrials.gov/study/NCT01761266
Trial related presentations / publications
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Vogel A, Tovoli F, Ueshima K, Aikata H, Lopez CL, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Tamai T, Saito K, Dutcus CE, Lencioni R. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. J Hepatol. 2023 Jan;78(1):133-141. doi: 10.1016/j.jhep.2022.09.006. Epub 2022 Sep 20.
Huynh J, Cho MT, Kim EJ, Ren M, Ramji Z, Vogel A. Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function. Ther Adv Med Oncol. 2022 Aug 24;14:17588359221116608. doi: 10.1177/17588359221116608. eCollection 2022.
Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, Lopez C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-658. doi: 10.1016/S2468-1253(21)00110-2. Epub 2021 Jun 2.
Okusaka T, Ikeda K, Kudo M, Finn R, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Mody K, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. J Gastroenterol. 2021 Jun;56(6):570-580. doi: 10.1007/s00535-021-01785-0. Epub 2021 May 4.
Briggs A, Daniele B, Dick K, Evans TRJ, Galle PR, Hubner RA, Lopez C, Siebert U, Tremblay G. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. Br J Cancer. 2020 Jun;122(12):1754-1759. doi: 10.1038/s41416-020-0817-7. Epub 2020 Apr 8.
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12.
Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW. Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. Br J Cancer. 2019 Jul;121(3):218-221. doi: 10.1038/s41416-019-0506-6. Epub 2019 Jun 28. Erratum In: Br J Cancer. 2019 Oct;121(7):625. doi: 10.1038/s41416-019-0534-2.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01761266